Your browser doesn't support javascript.
loading
Low testing rates limit the ability of genomic surveillance programs to monitor SARS-CoV-2 variants: a mathematical modelling study
Alvin X. Han; Amy Toporowski; Jilian A. Sacks; Mark Perkins; Sylvie Briand; Maria van Kerkhove; Emma Hannay; Sergio Carmona; Bill Rodriguez; Edyth Parker; Brooke E. Nichols; Colin A. Russell.
Afiliação
  • Alvin X. Han; Department of Medical Microbiology & Infection Prevention, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands
  • Amy Toporowski; Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland
  • Jilian A. Sacks; Department of Epidemic and Pandemic Preparedness and Prevention, Emergency Preparedness Programme, World Health Organization, Geneva, Switzerland
  • Mark Perkins; Department of Epidemic and Pandemic Preparedness and Prevention, Emergency Preparedness Programme, World Health Organization, Geneva, Switzerland
  • Sylvie Briand; Department of Epidemic and Pandemic Preparedness and Prevention, Emergency Preparedness Programme, World Health Organization, Geneva, Switzerland
  • Maria van Kerkhove; Department of Epidemic and Pandemic Preparedness and Prevention, Emergency Preparedness Programme, World Health Organization, Geneva, Switzerland
  • Emma Hannay; Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland
  • Sergio Carmona; Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland
  • Bill Rodriguez; Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland
  • Edyth Parker; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA
  • Brooke E. Nichols; Department of Medical Microbiology & Infection Prevention, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands
  • Colin A. Russell; Department of Medical Microbiology & Infection Prevention, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Preprint em Inglês | medRxiv | ID: ppmedrxiv-22275319
ABSTRACT
The first step in SARS-CoV-2 genomic surveillance is testing to identify infected people. However, global testing rates are falling as we emerge from the acute health emergency and remain low in many low- and middle-income countries (LMICs) (mean = 27 tests/100,000 people/day). We simulated COVID-19 epidemics in a prototypical LMIC to investigate how testing rates, sampling strategies, and sequencing proportions jointly impact surveillance outcomes and showed that low testing rates and spatiotemporal biases delay time-to-detection of new variants by weeks-to-months and can lead to unreliable estimates of variant prevalence even when the proportion of samples sequenced is increased. Accordingly, investments in wider access to diagnostics to support testing rates of [~]100 tests/100,000 people/day could enable more timely detection of new variants and reliable estimates of variant prevalence. The performance of global SARS-CoV-2 genomic surveillance programs is fundamentally limited by access to diagnostic testing.
Licença
cc_by_nc_nd
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo diagnóstico / Estudo observacional Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo diagnóstico / Estudo observacional Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
...